Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to preservation that represents a significant improvement over the traditional standard of care.
Paragonix Advanced Organ Preservation devices combine clinically-proven, stable cooling techniques with digital tracking and monitoring technologies to provide clinicians complete control and oversight throughout the donor organ journey. The clinical impact of Paragonix preservation technology is reinforced by the GUARDIAN clinical registries, the largest database of organ preservation data in the world that analyzes post-transplant outcomes in transplant recipients.
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Paragonix Technologies, Inc. today announced that it will be exhibiting at the International Society for Heart and Lung Transportation (ISHLT) 2019 Annual Meeting, from April 3 to 5 at the Loews Meeting Complex in Orlando, Florida. Paragonix executives will be at booth #409/411 providing hands-on demonstrations of its Paragonix SherpaPak™ Cardiac Transport System (CTS), the industry’s only FDA cleared and CE marked system for donor organ heart transport and storage.
Two clinical presentations will be given by Noritsugu Naito, MD, PhD from Massachusetts General Hospital (Boston, MA) on the hospital’s use of the Paragonix SherpaPak™ CTS:
Paragonix is also hosting the “2019 International Heart Summit” on April 4 from 12-2pm at ISHLT, bringing together heart transplant teams from the U.S. and Europe to share best practices and clinical experiences in adopting the Paragonix SherpaPak™ CTS as well as the opportunity to brainstorm and discuss new national and international standards for donor heart transport. Keynote talks at the presentation include:
“Paragonix has made tremendous strides in our quest to change the standard of care in how precious organs such as the heart are transported from donor to recipient patient and we are thrilled to bring together the world’s leading heart transplant surgeons to talk about the state of organ transport today and how to best prevent cold injury during transplants,” said Bill Edelman, Chairman and CEO of Paragonix Technologies.
The Paragonix SherpaPak™ CTS has been used by heart transplant centers in both the United States and Europe. The device is currently marketed in the United States, United Kingdom, France, Spain, Italy, Germany, Austria, Sweden and Slovak Republic in Europe.
About the International Society for Heart and Lung Transplantation
The International Society for Heart and Lung Transplantation (ISHLT), established in 1981, is a professional organization committed to research and education in heart and lung disease and transplantation. It holds annual scientific meetings and publishes The Journal of Heart and Lung Transplantation. It also holds the largest registry of heart and lung transplant data in the world.
About the Paragonix SherpaPak™ Cardiac Transport System
The Paragonix SherpaPak™ Cardiac Transport System (CTS) safeguards hearts during the journey from donor to recipient patient. Our device incorporates clinically proven and medically trusted cold preservation techniques in a novel suspension system to provide unprecedented physical and thermal protection. Paragonix SherpaPak™ CTS is the only commercially available FDA cleared and CE marked medical device for heart transportation.